Platform of Randomized Adaptive Clinical Trials in Critical Illness
NCT ID: NCT05440851
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
6250 participants
INTERVENTIONAL
2023-04-30
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Utilizing advances in Bayesian adaptive trial design, the platform will facilitate efficient yet rigorous testing of new treatments for AHRF, with a particular focus on mechanical ventilation strategies and extracorporeal life support techniques as well as pharmacological agents and new medical devices.
The platform is designed to enable evaluation of novel interventions at a variety of stages of investigation, including pilot and feasibility trials, trials focused on mechanistic surrogate endpoints for preliminary clinical evaluation, and full-scale clinical trials assessing the impact of interventions on patient-centered outcomes.
Interventions will be evaluated within therapeutic domains. A domain is defined as a set of interventions that are intended to act on specific mechanisms of injury using different variations of a common therapeutic strategy. Domains are intended to function independently of each other, allowing independent evaluation of multiple therapies within the same patient.
Once feasibility is established, Bayesian adaptive statistical modelling will be used to evaluate treatment efficacy at regular interim adaptive analyses of the pre-specified outcomes for each intervention in each domain. These adaptive analyses will compute the posterior probabilities of superiority, futility, inferiority, or equivalence for pre-specified comparisons within domains. Each of these potential conclusions will be pre-defined prior to commencing the intervention trial. Decisions about trial results (e.g., concluding superiority or equivalence) will be based on pre-specified threshold values for posterior probability. The primary outcome of interest, the definitions for superiority, futility, etc. (i.e., the magnitude of treatment effect) and the threshold values of posterior probability required to reach conclusions for superiority, futility etc., will vary from intervention to intervention depending on the phase of investigation and the nature of the intervention being evaluated. All of these parameters will be pre-specified as part of the statistical design for each intervention trial.
In general, domains will be designed to evaluate treatment effect within four discrete clinical states: non-intubated patients, intubated patients with low respiratory system elastance (\<2.5 cm H2O/(mL/kg)), intubated patients with high respiratory system elastance (≥2.5 cm H2O/(mL/kg)), and patients requiring extracorporeal life support. Where appropriate, the model will specify dynamic borrowing between states to maximize statistical information available for trial conclusions. In this perpetual trial design, different interventions may be added or dropped over time.
Where possible, the platform will be embedded within existing data collection repositories to enable greater efficiency in outcome ascertainment. Standardized systems for acquiring both physiological and biological measurements are embedded in the platform, to be acquired at sites with appropriate training, expertise, and facilities to collect those measurements.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-invasive Ventilation and Dex in Critically Ill Adults
NCT04878510
Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
NCT06066502
Wean Early With HFNCO vs NPPV in Patients With AHRF
NCT03171935
Comparison of Positive End Expiratory Pressure Titration Methods in ARDS Patients
NCT03281473
Sigh in Acute Hypoxemic Respiratory Failure
NCT03201263
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Invasive Mechanical Ventilation (IMV) Strategies domain: The IMV Strategies domain will evaluate multiple novel invasive ventilation strategies in comparison to conventional lung-protective ventilation in patients with acute hypoxemic respiratory failure (AHRF). Multiple approaches to mechanical ventilation are used, and the optimal approach is unknown. An efficient strategy to identify the best strategy is to compare multiple potential approaches simultaneously to determine more rapidly (a) which interventions are least effective (and should be dropped), and (b) which interventions result in the best outcomes for patients. In the current domain design, we will compare the current recommended ventilation strategy to two new approaches: a strategy that targets lung-inflating (driving) pressure instead of lung-inflating (tidal) volume, and a strategy that aims to maintain an optimal level of breathing effort to prevent diaphragm atrophy and injury while maintaining safe lung-inflating pressures.
CORT-E2 domain: The Corticosteroid Early and Extended (CORT-E2) Trial is a phase III, multicentre Bayesian randomized controlled trial (RCT), which includes two cohorts within the domain; one examining the role of early corticosteroids as compared to not extending in persisting AHRF due to COVID or non-COVID (Extended Cohort).
ESCAPE domain: Evaluating Subphenotypes in Immunocompromized Patients with ARF (ESCAPE) Domain is a prospective, multicentre observational cohort study, to identify subphenotypes across immunocompromised patients with acute hypoxemic respiratory failure (AHRF) using clinical characteristics and biomarkers. This study will prospectively collect biomarkers at the onset of AHRF which will allow us to characterize the underlying pathophysiology of AHRF with better precision.
FLUDRO domain: The Fludrocortisone in Acute Hypoxemic Respiratory Failure with Airspace Disease (FLUDRO-1) domain is a phase II I trial. The trial aims to provide direct clinical evidence to resolve a critical long-standing question regarding the use of steroids in the treatment of AHRF with airspace disease.
FAST-3 domain: The Nebulized Furosemide for the Treatment of Pulmonary Inflammation in Patients with Respiratory Failure Secondary to Pulmonary Infection domain is a phase III trial. It aims to use nebulized furosemide as supportive therapy to improve Advanced Respiratory Support (ARS) free days up to day 28 in critically ill patients with AHRF.
IMV-ECLS domain: The Invasive Mechanical Ventilation Strategies in Venovenous-Extracorporeal Life Support (PRESSURE; Positive Pressure to Maintain Lung Recruitment during Extracorporeal Life Support for Acute Hypoxemic Respiratory failure) is a pilot and feasibility trial. It aims to identify which positive end-expiratory pressure (PEEP) strategies improve lung function in patients with AHRF supported by ECLS.
IMPROV domain: The Inspiratory Muscle Training in Patients Receiving Ongoing Mechanical Ventilation is a pilot and feasibility RCT. It is designed to establish the feasibility of a definitive RCT of inspiratory muscle training to accelerate recovery from AHRF.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Where possible, clinical outcomes will be collected by research personnel who are masked to randomized treatment assignment. Even where research personnel cannot be blinded to treatment assignment, bias arising will be mitigated by selection of relatively objective endpoints not easily influenced by knowledge of treatment assignment.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ultra-protective ventilation facilitated by extracorporeal carbon dioxide removal.
Patients randomized to the this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
Ultra-Protective Ventilation Facilitated by Extracorporeal Support
Patients randomized to this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
Lung-Protective Ventilation (LPV)
Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation
Patients randomized to this intervention group will receive VV-ECMO where the sedation will be reduced and the ventilator will will be adjusted to facilitate spontaneous breathing.
Invasive Mechanical Ventilation (IMV) Strategies domain
Patients on invasive mechanical ventilation in the low elastance, high elastance, and ECLS states will be randomized to minimum of one of two mechanical ventilation interventions (including conventional lung-protective ventilation as a control group). Most sites will randomize patients to two arms (one of which is the control group, LPV). A subset of sites will randomize patients to all three or four arms.
Lung-Protective Ventilation (LPV)
Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
Driving Pressure-Limited Ventilation (DPL)
Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)
Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
Electrical impedance tomography (EIT)
Patients randomized to EIT will have PEEP titration compared via the Overdistension Collapse Intercept (ODCL) versus that obtained using a standard high PEEP table.
The Corticosteroid Early and Extended (CORT-E2) Randomized Controlled Trial domain
Patients with acute hypoxemic respiratory failure (AHRF) requiring invasive or non-invasive respiratory support will be randomized in the Early Cohort to receive corticosteroid or usual care without corticosteroids. Patients treated with corticosteroids who still require invasive or non-invasive respiratory support after 10 days will be randomized in the Extended Cohort to extending corticosteroid use or stopping corticosteroids after 10 days.
Early Cohort corticosteroid dose
Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
Extended Cohort corticosteroid dose
Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).
Usual care without routine corticosteroids
Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
Usual care without extending corticosteroids
Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
The Nebulized Furosemide for the Treatment of Pulmonary Inflammation (FAST-3) domain
Patients with Respiratory Failure Secondary to Pulmonary Infection.
4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours
40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours
The Invasive Mechanical Ventilation Strategies in Venovenous-Extracorporeal Life Support (IMV-ECLS)
Patients with acute hypoxemic respiratory failure receiving extracorporeal life support will be randomized to one of three positive end-expiratory pressure (PEEP) strategies.
PEEP-20
fixed high positive end-expiratory pressure at 20 cmH2O
PEEP-AOP
positive end-expiratory pressure set according to airway opening pressure
PEEP-10
fixed lower positive end-expiratory pressure at 10 cmH2O
The Fludrocortisone in Acute Hypoxemic Respiratory Failure with Airspace Disease (FLUDRO-1) domain
Patients with acute hypoxemic respiratory failure with airspace disease will be randomized to usual care with or without fludrocortisone.
Usual care with fludrocortisone
Best practice standard of care prescribed by treating team + fludrocortisone 50μg enterally daily for 7 days.
Usual care without fludrocortisone
Best practice standard of care prescribed by treating team without fludrocortisone. After randomization, if a clinical indication develops for fludrocortisone as part of standard of care, administration of fludrocortisone is not prohibited. Any fludrocortisone administered to participants in the control arm will be documented.
VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation
Patients with acute hypoxemic respiratory failure in the high elastance state will be randomized to ultra-protective ventilation facilitated by extracorporeal carbon dioxide removal or to VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation or to conventional lung-protective ventilation.
Ultra-Protective Ventilation Facilitated by Extracorporeal Support
Patients randomized to this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
Lung-Protective Ventilation (LPV)
Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation
Patients randomized to this intervention group will receive VV-ECMO where the sedation will be reduced and the ventilator will will be adjusted to facilitate spontaneous breathing.
Evaluating Subphenotypes in Immunocompromized Patients with ARF (ESCAPE) Domain
We will conduct a prospective, multicenter, observational study (no treatment arm is involved) in 7 ICUs in Canada over 3 years. We will include adult patients (≥18 years) admitted to the ICU with AHRF who have an underlying immunocompromised condition.
Biomarker Collection: Samples for serum biomarkers will be collected within 24 hours of fulfilling inclusion criteria, on days 0, 3 and 7. We will collect biomarkers associated with inflammatory conditions, epithelial injury, endothelial dysfunction and coagulation abnormalities - which have been shown to characterize lung injury or critical illness.
Data Collection: We will collect demographic, comorbidity, immunocompromised defining condition, clinical, respiratory physiology, and serum biomarker data for each patient.
no treatment / intervention arm is involved
This trial is a prospective, multicenter, observational study (no treatment arm is involved).
Inspiratory Muscle Training in Patients Receiving Ongoing Mechanical Ventilation (IMPROV) Domain
This domain studies inspiratory muscle training (IMT) during and after mechanical ventilation in patients with acute hypoxemic respiratory failure (AHRF).
Usual care
Patients will be treated according to usual care.
Early Routine IMT
* Training commences once patients meet readiness to wean criteria
* 3 sets of 10 breaths, delivered twice daily using a device placed at the airway opening to apply an external resistive pressure load, until hospital discharge, death, or day 45 after randomization, whichever occurs first.
* Device load will initially be set to 30% of the MIP.
* Device load will be titrated upward (in increments of 5-10% of MIP, to a maximum of 60% of MIP) as needed to achieve a modified Borg dyspnea score of 7/10 or visible accessory muscle use.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultra-Protective Ventilation Facilitated by Extracorporeal Support
Patients randomized to this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
Lung-Protective Ventilation (LPV)
Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
Driving Pressure-Limited Ventilation (DPL)
Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)
Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
Early Cohort corticosteroid dose
Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
Extended Cohort corticosteroid dose
Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).
Usual care without routine corticosteroids
Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
Usual care without extending corticosteroids
Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
Usual care with fludrocortisone
Best practice standard of care prescribed by treating team + fludrocortisone 50μg enterally daily for 7 days.
Usual care without fludrocortisone
Best practice standard of care prescribed by treating team without fludrocortisone. After randomization, if a clinical indication develops for fludrocortisone as part of standard of care, administration of fludrocortisone is not prohibited. Any fludrocortisone administered to participants in the control arm will be documented.
4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours
40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours
PEEP-20
fixed high positive end-expiratory pressure at 20 cmH2O
PEEP-AOP
positive end-expiratory pressure set according to airway opening pressure
PEEP-10
fixed lower positive end-expiratory pressure at 10 cmH2O
VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation
Patients randomized to this intervention group will receive VV-ECMO where the sedation will be reduced and the ventilator will will be adjusted to facilitate spontaneous breathing.
Electrical impedance tomography (EIT)
Patients randomized to EIT will have PEEP titration compared via the Overdistension Collapse Intercept (ODCL) versus that obtained using a standard high PEEP table.
no treatment / intervention arm is involved
This trial is a prospective, multicenter, observational study (no treatment arm is involved).
Usual care
Patients will be treated according to usual care.
Early Routine IMT
* Training commences once patients meet readiness to wean criteria
* 3 sets of 10 breaths, delivered twice daily using a device placed at the airway opening to apply an external resistive pressure load, until hospital discharge, death, or day 45 after randomization, whichever occurs first.
* Device load will initially be set to 30% of the MIP.
* Device load will be titrated upward (in increments of 5-10% of MIP, to a maximum of 60% of MIP) as needed to achieve a modified Borg dyspnea score of 7/10 or visible accessory muscle use.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. New or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support
2. Receiving any of the following types of oxygen or respiratory support for at least 4 hours prior to the time of randomization; supplemental oxygen at 10 L/min or higher, high flow nasal oxygen (at any flow rate), invasive ventilator support, extra-corporeal life support (ECLS), or non-invasive ventilator support
3. Minimum FiO2 ≥ 0.40 (for venturi mask, high flow nasal cannula, or invasive or non-invasive ventilation) or oxygen flow rate ≥10 L/min on face mask for at least 4 hours at the time of evaluation for eligibility unless already on extra-corporeal life support
2. Age ≥ 18 years
3. Hypoxemia not primarily attributable to acute heart failure, fluid overload, or pulmonary embolism (PE)
1. Receiving invasive Endotracheal mechanical ventilation for ≤ 72 hours.5 days
2. Early Moderate-severe hypoxemic respiratory failure with a PaO2/FiO2≤150200 mmHg for at least 6 hours
7. Severe hypoxemia with PaO2/FiO2 \< 80mmHg for \> 6 hours at time of screening.
8. Severe hypercapnic respiratory failure with pH \< 7.25 and PaCO2 \> 60 mmHg for \> 6 hours at time of screening.
9. Expected mechanical ventilation duration \< 48 hours at time of screening.
10. Confirmed diffuse alveolar hemorrhage from vasculitis.
11. Contraindications to limited anticoagulation (e.g., active GI bleeding, bleeding diathesis).
12. Previous hypersensitivity/anaphylactic reaction to heparin or heparin-induced thrombocytopenia
13. Neurologic conditions at risk for or undergoing treatment for intracranial hypertension
14. Underlying illness with life expectancy \< 1 year
15. Pregnancy (due to unknown effects of PaCO2 changes on placental blood flow)
16. Respiratory failure known or suspected to be caused by COVID-19.
1. Intubated patients, not on ECLS, with low normalized respiratory elastance (\<2.5 cm H2O/(ml/kg predicted body weight)) at the time of eligibility assessment OR
2. Intubated patients, not on ECLS, with high normalized respiratory system elastance (≥2.5 cm H2O/(ml/kg predicted body weight)) at the time of eligibility assessment OR
3. FOR STUDY SITES PARTICIPATING IN THE LDPVS INTERVENTION: Patient is on ECLS at the time of eligibility assessment. Note: Patients in this state are only eligible for the LPV or LDPVS intervention
4. FOR STUDY SITES PARTICPATING IN THE EIT INTERVENTION: PaO2/FiO2 (if available) \< 200 mm Hg at randomization. If PaO2/FiO2 has not been measured, SpO2 = 97% on FiO2 =60%.
1. Within 72 hours of admission to an ICU
2. New unilateral or bilateral airspace disease
1. Are admitted to an ICU
2. Have already received 10 days of corticosteroid specifically for acute respiratory failure, this will include patients: (a) randomized to corticosteroid arm in Early Cohort, (b) patients with COVID receiving corticosteroids as standard of care , (c) and others who have received corticosteroids for AHRF
3. Ongoing AHRF requiring HFNC, NIV (continuous positive airway pressure \[CPAP\] or bilevel) or invasive ventilation
1\. Within 72 hours of admission to an ICU
1. Patient is in a PRACTICAL eligible platform state and requires advanced respiratory support (ARS) defined as one of the following:
a. Invasive mechanical ventilation with FiO2 \> 40% b. Non-Invasive Ventilation (\> 4 hours consecutively with FiO2 \> 40%) defined as: i. CPAP or BiPAP (any settings or interface) ii. HFNC (flow \> 40 liter per minute)
2. PaO2/FiO2 \< 300 mm Hg or SpO2/FiO2 \< 315 (if PaO2/FiO2 unavailable due to lack of arterial blood gas at the time of screening). For SpO2/FiO2, criteria are SpO2 ≤ 97% on FiO2 ≥ 40% on both of the 2 hours immediately preceding eligibility assessment. If an arterial blood gas can be obtained, then a PaO2/FiO2 ratio is preferable.
3. Patient commenced advanced respiratory support \< 48 hours prior to randomization.
1. Patients with severe AHRF who have an underlying immunocompromised condition
Patients may be enrolled from the wards or ICU.
Immunocompromised patients include:
1. Any patients requiring long term (\>30 days) corticosteroids (\>20 mg/day),
2. Any patients receiving non-corticosteroid immunosuppressive medications within the prior 3 months,
3. Acquired or inherited immunodeficiency syndrome,
4. Recipients of solid organ transplant,
5. Active hematologic malignancy (diagnosis or receiving treatment within prior 6 months),
6. Active solid tumor (diagnosis or receiving treatment within the prior 6 months) or
7. Any patients who have undergone allogeneic or autologous hematopoietic cell transplant in the prior 6 months (HCT).
1\. Patients receiving invasive mechanical ventilation for AHRF as defined by the PRACTICAL platform trial criteria above.
2\. Within 7 calendar days of intubation
Exclusion Criteria
2. ICU discharged is planned or anticipated on the day of screening
3. If the patient is moribund and deemed unlikely to survive 24 hours (as determined by the clinical team)
4. If the patient is being transitioned to a fully palliative philosophy of care
1. Patients over 70 years of age.
2. Currently receiving any form of ECLS (e.g., Venovenous, venoarterial, or hybrid configuration).
3. Chronic hypercapnic respiratory failure defined as PaCO2 \> 60 mmHg in the outpatient setting.
4. Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP/BiPAP used solely for sleep-disordered breathing.
5. Actual body weight exceeding 1 kg per centimeter of height.
1\. PaO2/FiO2 \>300 mm Hg or (S/F \>250, if PaO2/FiO2 has not been measured) at the time of randomization 2. Chronic hypercapnic respiratory failure defined as PaCO2\>60mmHg in the outpatient setting 3. Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not including nocturnal CPAP applied by nasal or face mask or home tracheotomy if not ventilated 4. Severe hypoxemia with PaO2/FiO2\<80mmHg for \>6 consecutive hours at the time of randomization 5. Severe hypercapnic respiratory failure with pH\<7.25 and PaCO2\>60mmHg for \>6 consecutive hours at the time of randomization 6. Anticipated duration of mechanical ventilation is \<48 hours from the time of screening 7. Duration of mechanical ventilation during current ICU admission is \>72 hours 8. Previously diagnosed neuromuscular disorder 9. Current diagnosis of severe acute brain injury (e.g. ischemic or hemorrhagic stroke, traumatic brain injury) with Glasgow Coma Scale ≤ 8 10. Baseline weight prior to or at hospital admission less than 35 kilograms 11. Receiving extracorporeal life support without continuous invasive mechanical ventilatory support
1. Receiving only low flow oxygen therapy less than or equal to 15L/min
2. Corticosteroid use during the 14 days prior to screening
3. Existing indication for corticosteroids
4. High suspicion for/or confirmed COVID infection
5. Acute traumatic brain injury during the index hospital admission
6. Allergy to dexamethasone
1. An alternate indication for ongoing corticosteroids
2. Acute traumatic brain injury this hospital admission
1. Known hypersensitivity to fludrocortisone
2. An inability to receive fludrocortisone due to lack of enteral access
3. An indication to prescribe fludrocortisone for a reason that is unrelated to a current episode of pneumonia or acute respiratory failure, such as Addison's disease
4. Belief of the treating clinical team that study participation would not be in the best interest of the patient
1. Patient commenced advanced respiratory support \> 48 hours to time of randomization.
2. Known history of severe chronic pulmonary disease e.g., pre-infection requirement for home oxygen therapy or presence of chronic hypercapnia (PaCO2 \> 60 mmHg); mild - moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy.
3. Currently enrolled in another trial studying investigational anti-inflammatory therapy, excluding established treatments used in clinical practice such as corticosteroids.
4. Known allergy to furosemide or sulfonamide drugs. If the patient is allergic to sulfonamide drugs but has received in the past or is currently receiving furosemide without incident, they can be enrolled since cross-reactivity between furosemide and sulfonamide agents is rare.
1. Patient is expected to be liberated from mechanical ventilation within 24 hours
2. Known or suspected chronic hypercapnic respiratory failure defined as PaCO2\>60mmHg in the outpatient setting
3. Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not including nocturnal CPAP applied by nasal or face mask or home tracheotomy if not ventilated
4. Known pneumothorax or pneumomediastinum without chest tube placement sustained during current ICU admission\* (re-confirm immediately prior to randomization)
5. Patient is admitted primarily for acute brain injury (stroke, traumatic brain injury, etc.)
6. Previously diagnosed chronic neuromuscular disorder
7. Patient has an implantable cardiac defibrillator or pacemaker
8. Planned to be transferred to another hospital before ICU discharge
9. Already receiving a regimen of inspiratory muscle training using external resistive device or diaphragm neurostimulation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Health Network, Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ewan Goligher, MD, PhD
Role: STUDY_CHAIR
University Health Network, Toronto
Eddy Fan, MD, PhD
Role: STUDY_CHAIR
University Health Network, Toronto
Niall Ferguson, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
University Health Network, Toronto
Lorenzo Del Sorbo, MD
Role: PRINCIPAL_INVESTIGATOR
University Health Network, Toronto
Bram Rochwerg, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
McMaster University
Bijan Teja, MD
Role: PRINCIPAL_INVESTIGATOR
Unity Health Toronto
John Muscedere, MD
Role: PRINCIPAL_INVESTIGATOR
Queens University
Laveena Munshi, MD
Role: PRINCIPAL_INVESTIGATOR
Mount Sinai Hospital, Canada
Dmitry Rozenberg, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Health Network, Toronto
Anastasia Newman, PhD
Role: PRINCIPAL_INVESTIGATOR
McMaster University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arizona
Tucson, Arizona, United States
University of California Los Angeles (UCLA)
Los Angeles, California, United States
University of San Diego (UCSD)
San Diego, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
University of Kentucky
Lexington, Kentucky, United States
University of Maryland Medical System
Baltimore, Maryland, United States
The Johns Hopkins Medicine
Baltimore, Maryland, United States
VA Ann Arbor Healthcare System
Ann Arbor, Michigan, United States
University of Michigan Health
Ann Arbor, Michigan, United States
Washington University
St Louis, Missouri, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Mount Sinai New York City
New York, New York, United States
Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States
University of Cincinnati College of Medicine
Cincinnati, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
Oregon Health & Science University (OHSU)
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Medical University of South Carolina (MUSC)
Charleston, South Carolina, United States
Vanderbilt university medical center
Nashville, Tennessee, United States
University of Utah Health
Farmington, Utah, United States
Sentara Health
Norfolk, Virginia, United States
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Nepean Hospital
Kingswood, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
Flinders Medical Centre
Bedford Park, Southern Adelaide, Australia
St Vincents Sydney
Darlinghurst, Sydney, Australia
Bendigo Health Victoria
Bendigo, Victoria, Australia
University Hospital Geelong
Geelong, Victoria, Australia
The Austin Hospital
Heidelberg, Victoria, Australia
University of Calgary
Calgary, Alberta, Canada
University of Alberta/Edmonton University Hospital
Edmonton, Alberta, Canada
Nanaimo Regional General Hospital
Nanaimo, British Columbia, Canada
Surrey Memorial Hospital
Surrey, British Columbia, Canada
St. Paul's Hospital
Vancouver, British Columbia, Canada
Royal Jubilee Hospital
Victoria, British Columbia, Canada
St. Boniface Hospital
Winnipeg, Manitoba, Canada
Health Sciences Centre - Winnipeg
Winnipeg, Manitoba, Canada
Grace Hospital
Winnipeg, Manitoba, Canada
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
William Osler Health System
Brampton, Ontario, Canada
Brantford General Hospital
Brantford, Ontario, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
Oak Valley Health
Markham, Ontario, Canada
North York General Hospital
North York, Ontario, Canada
Lakeridge Hospital
Oshawa, Ontario, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
Ottawa Heart Research Institute
Ottawa, Ontario, Canada
Mackenzie Health
Richmond Hill, Ontario, Canada
Niagara Health Systems
Saint Catherines, Ontario, Canada
Scarborough Health Network
Toronto, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Unity Health Toronto
Toronto, Ontario, Canada
Sinai Health, Mount Sinai Hospital
Toronto, Ontario, Canada
Cortellucci Vaughan Hospital
Vaughan, Ontario, Canada
Windsor Regional Health
Windsor, Ontario, Canada
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
MUHC - McGill University Health Centre (Glen Site)
Montreal, Quebec, Canada
Sacre Coeur du Montreal
Montreal, Quebec, Canada
Centre Hospitalier Universite de Sherbrooke
Sherbrooke, Quebec, Canada
Trois Riviere (CHAUR)
Trois-Rivières, Quebec, Canada
Royal University Saskatoon
Saskatoon, Saskatchewan, Canada
University Health Network
Toronto, , Canada
Clínica Universidad de La Sabana
Chía, Cundinamarca, Colombia
Azienda Socio-Sanitaria Territoriale Ovest Milanese
Legnano, MI, Italy
Ospedale Maggiore, Fondazione IRCCS Ca Granda, Milano
Milan, MI, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, MI, Italy
Auckland City Hospital
Grafton, Auckland, New Zealand
Middlemore Hospital
Auckland, , New Zealand
Taranaki Base Hospital
New Plymouth, , New Zealand
Rotorua Hospital
Rotorua, , New Zealand
King Abdulaziz Medical City- Riyadh
Riyadh, , Saudi Arabia
National University of Singapore
Singapore, , Singapore
Parc Taulí University Hospital
Sabadell, Barcelona, Spain
Hospital Universitario de Getafe
Getafe, Madrid, Spain
Hospital Josep Trueta (Girona)
Girona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-5940
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.